Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial

Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial

Abstract Background The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide ant...

Full description

Bibliographic Details
Main Authors: Iwein Gyselinck, Laurens Liesenborgs, Ewout Landeloos, Ann Belmans, Geert Verbeke, Peter Verhamme, Robin Vos, W. Janssens, on behalf of the DAWn-Azithro consortium
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Trials
Subjects:
SARS-CoV-2
COVID-19
Azithromycin
Macrolide
Antiviral
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-021-05033-x

Internet

https://doi.org/10.1186/s13063-021-05033-x

Similar Items